Trial
Vascular Surgery

Assessment of the GORE® EXCLUDER® Conformable AAA Endoprosthesis in the Treatment of Abdominal Aortic Aneurysms: AAA 13-03

Active not recruiting

The purpose of this study is to assess the safety and effectiveness of the GORE® EXCLUDER® Conformable AAA Endoprosthesis (Study Device) when used for the treatment of Abdominal Aortic Aneurysms (AAA).

Contact: Kristal Adams 217-545-7812
News

Report, Webinar Focus on Impact of COVID-19 and the Opioid Epidemic

SPRINGFIELD, IL – A new report describes the impact of COVID-19 on the existing rural opioid epidemic and identified opportunities to treat opioid addiction and reduce fatalities in rural Illinois. “The opioid epidemic continues to hurt rural regions in Illinois and the pandemic has worsened the economic and social factors that lead to opioid misuse,” said Dr. Sameer Vohra, Chair, SIU Medicine Department of Population Science and Policy. “We need to invest in new strategies and resources that prevent, treat and build appropriate systems of recovery for those struggling from the opioid epidemic
News

Report, Webinar Focus on Impact of COVID-19 and the Opioid Epidemic

SPRINGFIELD, IL – A new report describes the impact of COVID-19 on the existing rural opioid epidemic and identified opportunities to treat opioid addiction and reduce fatalities in rural Illinois. “The opioid epidemic continues to hurt rural regions in Illinois and the pandemic has worsened the economic and social factors that lead to opioid misuse,” said Dr. Sameer Vohra, Chair, SIU Medicine Department of Population Science and Policy. “We need to invest in new strategies and resources that prevent, treat and build appropriate systems of recovery for those struggling from the opioid epidemic
Trial
Neurology

MDA: Neuromuscular Observational Research

Active recruiting

MOVR:  Data Hub is the first and only data hub that aggregates clinical, genetic, and patient reported data for multiple nuromuscular diseases.  Collection of patient data about disease progression in the era of new treatments will inform and accelerate future innovation.  The combination of data collected through MOVR Data Hub will provide a comprehensive understanding of health and patient experiences in a single data repository.  MOVR Data Hub has the power to transform health outcomes, accelerate drug development and drive clinical research across multiple neuromuscu

Contact: Stephanie Kohlrus 217-545-3013
Trial
Neurology

Caregiver Characteristics That May Predict When Patients With Alzheimer Disease Are Placed in Long Term Care Facilities

Active recruiting
This research will be conducted by the SIU Memory and Aging Network (MAN), which comprises 38 sites that evaluate and treat patients with dementia throughout non-metropolitan Illinois.  AD patients and their caregivers who are living in private homes will be recruited.  Primary outcome measures will be the ratings of the caregiver’s physical status (grip strength, walking speed, and score on the Timed Up-and-Go Test11 and the rating of the caregiver’s chronic medical illness burden using the Cumulative Illness Rating Scale (Geriatric).12,13  The patient and caregiver dyad is required.
Contact: Stephanie Kohlrus 217-545-3013
Trial
Neurology

Caregiver Characteristics That May Predict When Patients With Alzheimer Disease Are Placed in Long Term Care Facilities

Active recruiting
This research will be conducted by the SIU Memory and Aging Network (MAN), which comprises 38 sites that evaluate and treat patients with dementia throughout non-metropolitan Illinois.  AD patients and their caregivers who are living in private homes will be recruited.  Primary outcome measures will be the ratings of the caregiver’s physical status (grip strength, walking speed, and score on the Timed Up-and-Go Test11 and the rating of the caregiver’s chronic medical illness burden using the Cumulative Illness Rating Scale (Geriatric).12,13  The patient and caregiver dyad is required.
Contact: Stephanie Kohlrus 217-545-3013
Trial
Neurology

Roche: A Phase IIB, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of intravenous prasinezumab in participants with early Parkinson's disease

Active not recruiting

This study will evaluate the efficacy, safety, and pharmacokinetics of prasinezumab compared with placebo in patients with early Parkinson's disease (PD).

Contact: Rylee Manka 217-545-1394
Trial
Psychiatry

RECOVER: A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy System as Adjunctive Therapy Versus a No-Stimulation Control in Subjects with Treatment-Resistant Depression

Active recruiting

The RECOVER study is a nationwide clinical trial that has been approved by Medicare to provide additional evidence for the benefits of Vagus Nerve Stimulation (VNS) Therapy.  Vagus Nerve Stimulation Therapy is an FDA-approved device for treating patients with TRD (Treatment Resistant Depression). It is implanted in the left chest area during a short outpatient procedure. The device delivers mild, intermittently pulsed signals to the vagus nerve in the neck that activate various parts of the brain.

Contact: Oladele (Dickson) Owasoyo 217-545-7231
News

SIU Medicine enrolling patients for clinical study to treat depression

SPRINGFIELD, ILLINOIS, October 18, 2021 – Clinical depression affects more than 17 million people in the United States. Among those afflicted, 1 out of 3 has what is called treatment-resistant depression (TRD). Despite medical help, they have been unable to find adequate relief from their symptoms. A new clinical trial at SIU School of Medicine is testing a treatment that could help those with recurring depression. “Depression is a common mental disorder that can become disabling if not treated,” said Jeffrey Bennett, MD, professor of psychiatry at SIU School of Medicine and the principal
News

SIU Medicine enrolling patients for clinical study to treat depression

SPRINGFIELD, ILLINOIS, October 18, 2021 – Clinical depression affects more than 17 million people in the United States. Among those afflicted, 1 out of 3 has what is called treatment-resistant depression (TRD). Despite medical help, they have been unable to find adequate relief from their symptoms. A new clinical trial at SIU School of Medicine is testing a treatment that could help those with recurring depression. “Depression is a common mental disorder that can become disabling if not treated,” said Jeffrey Bennett, MD, professor of psychiatry at SIU School of Medicine and the principal
Subscribe to Research